• James River Coal Company (NASDAQ:JRCC) upgrads to a sector outperform rating
  • Reports On Yahoo! Inc. (NASDAQ:YHOO) Board Approval For Tumbler Inc. – GOOG, FB
  • Genco Shipping & Trading Ltd. (NYSE:GNK) shares increase by 16.30%
  • JP Morgan Chase & Co. (NYSE:JPM) Stock To Decline
  • FDA Approves Drug By GlaxoSmithKline Plc. (NYSE:GSK) And Theravance Inc. (NASDAQ:THRX)
Recent Posts
  • James River Coal Company (NASDAQ:JRCC) upgrads to a sector outperform rating
  • Reports On Yahoo! Inc. (NASDAQ:YHOO) Board Approval For Tumbler Inc. – GOOG, FB
  • Genco Shipping & Trading Ltd. (NYSE:GNK) shares increase by 16.30%
  • JP Morgan Chase & Co. (NYSE:JPM) Stock To Decline
  • FDA Approves Drug By GlaxoSmithKline Plc. (NYSE:GSK) And Theravance Inc. (NASDAQ:THRX)
  • Groupon Inc. (NASDAQ:GRPN) Rises With Increasing Revenues
  • Coca Cola Co. (NYSE:KO) To Fight Obesity – PEP
  • Christie Raises $6.2 Million For Reelection Bid
  • UnitedHealth Group Inc (NYSE:UNH) faces flak from Pentagon
  • Goldman Sachs Group, Inc (NYSE:GS) $31 million tax evasion under scrutiny – GOOG, SBUX

Business

FDA Approves Drug By GlaxoSmithKline Plc. (NYSE:GSK) And Theravance Inc. (NASDAQ:THRX)

May 13, 2013 by Mike Anderson in Business with 0 Comments

Northern, WI 05/13/2013 (tradewatchmedia) – The decade long partnership between GlaxoSmithKline Plc. (NYSE:GSK) (Closed: $51.62, Up by 1.81%) and Theravance Inc. (NASDAQ:THRX) (closed: $34.94, Up by 11.59%) has finally won the United States FDA approval for its drug Breo Ellipta. The drug is used to treat lung disorder and could be administered once a day to the patients.

Breo Ellipta

The drug developed by the partners would work by decreasing inflammation around the lungs and by helping relaxation around the airways. Breo Ellipta would help in the treatment of Chronic Obstructive Pulmonary Disease, COPD and airflow obstruction. It had been observed that this form of lung disorder had been the third leading cause of death in the United States.

However, Breo Ellipta developed by GlaxoSmithKline Plc. (NYSE:GSK) and Theravance Inc. (NASDAQ:THRX) comes with a warning that it contains the risk of increasing asthma related drugs and that it is not for young children under 18 years. This treatment is the first of its kind medicine developed by the partners to get FDA approval.

Revenue Generation

Breo Ellipta would generate $4 billion in worldwide sales at the highest level and this would in turn get converted to $500 million in royalties to Theravance Inc. (NASDAQ:THRX). On the other hand, Theravance Inc. (NASDAQ:THRX) would pay $30 million to GlaxoSmithKline Plc. (NYSE: GSK) following the Food and Drug Administration approval of the drug. The partnership companies are also working on another drug for lung disorder treatment, named Anoro, which would go for FDA approval in December.

Tagged , , ,

About Mike Anderson

Mike Anderson started in Economy and markets, but soon made the switch as editor. While in school, Mike had television internships in Washington D.C., New York City, and Dublin. Mike was also been integral part of nonprofit for citizen activists, and has worked at The Heritage Foundation, Hills dale College's Washington office, the U.S. Chamber of Commerce and the senior levels of the legislative and executive branches of government. Mike covered the U.S. House for Roll Call. He has also worked for Congress Daily, covering the House, Senate and campaign finance beats.

View all posts by Mike Anderson →

Related Posts

Leave a reply

Your email address will not be published. Required fields are marked *

*

Trade Watch Media Company
Trade Watch Media Company 320 North Dearborn Street Chicago, IL

Contact Us / Phone Us

  • Support:312-744-1856
  • Media:312-744-1932
  • Sales:312-744-1933
Trending..
  • James River Coal Company (NASDAQ:JRCC) upgrads to a sector outperform rating
  • Reports On Yahoo! Inc. (NASDAQ:YHOO) Board Approval For Tumbler Inc. – GOOG, FB
  • Genco Shipping & Trading Ltd. (NYSE:GNK) shares increase by 16.30%
  • JP Morgan Chase & Co. (NYSE:JPM) Stock To Decline
  • FDA Approves Drug By GlaxoSmithKline Plc. (NYSE:GSK) And Theravance Inc. (NASDAQ:THRX)